DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Plotkin MD, Kaplan MR, Verlander JW, et al. Localization of
the thiazide-sensitive Na–Cl cotransporter rTSCl in the rat kidney.
Kidney Int, 1996, 50:174–183.
Ramires, F.J., Mansur, A., Coelho, O., et al. Effect of spironolactone
on ventricular arrhythmias in congestive heart failure
secondary to idiopathic dilated or to ischemic cardiomyopathy.
Am J Cardiol, 2000, 85:1207–1211.
Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin
III: A central regulator of vasopressin release and
blood pressure. Trends Endocrinol Metab, 2001, 12:157–162.
Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations
of loop and thiazide diuretics on calcium homeostasis: A
randomized, double-blinded, Latin-square, multiple cross-over
study in postmenopausal osteopenic women. Eur J Clin Invest,
2003, 33:41–50.
Robertson GL. Regulation of vasopressin secretion. In, The
Kidney: Physiology and Pathophysiology, vol. 2, 2nd ed.
(Seldin DW, Giebisch G, eds.) Raven Press, New York, 1992,
pp. 1595–1613.
Robertson GL. Antidiuretic hormone, normal and disordered
function. Endocrinol Metab Clin North Am, 2001, 30:
671–694.
Robertson GL, Athar S, Shelton RL. Osmotic control of vasopressin
function. In, Disturbances in Body Fluid Osmolality.
(Andreoli TE, Grantham JJ, Rector FC, eds.) American
Physiological Society, Bethesda, MD, 1977, pp. 125–148.
Sands JM. Molecular mechanisms of urea transport. J Membrane
Biol, 2003, 191:149–163.
Sciarrone MT, Stella P, Barlassina C, et al. ACE and α-adducin
polymorphism as markers of individual response to diuretic
therapy. Hypertension. 2003, 41:398–403.
Serradeil-Le Gal C, Wagnon J, Simiand J, et al. Characterization
of (2S,4R)-1-[5-chloro-1-[2,4-dimethoxyphenyl)sulfonyl]-3-
(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-
hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415),
a selective and orally active vasopressin V 1b
receptor antagonist.
J Pharmacol Exp Ther, 2002, 300:1122–1130.
Simon DB, Lifton RP. Mutations in Na(K)Cl transporters in
Gitleman’s and Bartter’s syndromes. Curr Opin Cell Biol,
1998, 10:450–454.
Snyder HM, Noland TD, Breyer MD. cAMP-dependent protein
kinase mediates hydro-osmotic effect of vasopressin in collecting
duct. Am J Physiol, 1992, 263:C147–C153.
Takeda M, Yoshitomi K, Imai M. Regulation of Na + –3HCO 3
–
cotransport in rabbit proximal convoluted tubule via adenosine
A 1
receptor. Am J Physiol, 1993, 265:F511–F519.
Tsuruoka S, Schwartz GJ. HCO 3−
absorption in rabbit outer
medullary collecting duct: Role of luminal carbonic anhydrase.
Am J Physiol, 1998, 274:F139–F147.
van Buren M, Bijlsma JA, Boer P, et al. Natriuretic and hypotensive
effect of adenosine-1 blockade in essential hypertension.
Hypertension, 1993, 22:728–734.
Velazquez H, Bartiss A, Bernstein P, Ellison DH. Adrenal
steroids stimulate thiazide-sensitive NaCl transport by rat renal
distal tubules. Am J Physiol, 1996, 270:F211–F219.
Vlavianos P, Westaby D. Management of acute variceal
haemorrhage. Eur J Gastroenterol Hepatol, 2001, 13:335–342.
Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone,
a selective aldosterone blocker, in mild to moderate hypertension.
Am J Hypertens, 2002, 15:709–716.
Wells T. Vesicular osmometers, vasopressin secretion and aquaporin-4:
A new mechanism for osmoreception? Mol Cell
Endocrinol, 1998, 136:103–107.
White WB, Carr AA, Krause S, et al. Assessment of the novel
selective aldosterone blocker eplerenone using ambulatory and
clinical blood pressure in patients with systemic hypertension.
Am J Cardiol, 2003, 92:38–42.
Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin
receptor antagonist (VPA-985) improves serum sodium
concentration in patients with hyponatremia: A multicenter,
randomized, placebo-controlled trial. Hepatology, 2003, 37:
182–191.
Wong LL, Verbalis JG. Vasopressin V 2
receptor antagonists.
Cardiovasc Res, 2001, 51:391–402.
Xu JC, Lytle C, Zhu TT, et al. Molecular cloning and functional
expression of the bumetanide-sensitive Na–K–Cl cotransporter.
Proc Natl Acad Sci USA, 1994, 91:220l–2205.
Yancy CY. Benefit-risk assessment of nesiritide in the treatment
of acute decompensated heart failure. Drug Safety, 2007,
30:765–781.
719
CHAPTER 25
REGULATION OF RENAL FUNCTION AND VASCULAR VOLUME